Neurol. pro Praxi, 2002; 5: 256-259

Imunomodulační terapie u sclerosis multiplex

MUDr. Pavel Štourač Ph.D
Neurologická klinika LF MU, Centrum pro demyelinizační onemocnění, FN Brno-Bohunice

Keywords: sclerosis multiplex, imunomodulační terapie, interferon beta-1a, interferon beta-1b, glatiramer acetát.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štourač P. Imunomodulační terapie u sclerosis multiplex. Neurol. praxi. 2002;3(5):256-259.

Imunomodulační terapie u sclerosis multiplex zahrnuje léčbu interferonem beta-1a, beta-1b a glatiramer acetátem. Jedná se o dlouhodobou léčbu zasahující na různých úrovních a různými mechanizmy do imunopatogeneze choroby. Klinické ovlivnění přirozeného průběhu choroby spočívá ve snížení počtu atak a omezení jejich tíže, v redukci patologicky změněné tkáně CNS na MR a ve zpomalení progrese onemocnění. Léčba je indikována pro pacienty v atakovité fázi onemocnění splňující kriteria biologické aktivity choroby. V současnosti jsou k dispozici čtyři typy imunomodulačních preparátů: interferon beta-1b (Betaferon), interferon beta-1a (Rebif 22 a 44), interferon beta-1a (Avonex) a glatiramer acetát (Copaxone). Klinický účinek těchto preparátů je prokázán studiemi splňujícími náročné metodologické postupy a statistické vyhodnocení, bez nichž není možno definitivně potvrdit či vyvrátit účinnost preparátu zejména u tak variabilně probíhající choroby jakou je sclerosis multiplex. V následujícím textu jsou shrnuty údaje týkající se podstatných aspektů jednotlivých studií zejména s ohledem na klinickou praxi.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cohen J. Statistical power analysis for the behavioral sciences,2nd ed. Hillsdale, NJ; Lawrence Erlbaum Associates: 1988.
    2. Cohen JA, Goodman AD,Heidenreich FR,et. Al. Results of IMPACT, a phase 3 trial of interferon beta- 1a in secondary progressive MS. Neurology 2001; suppl.3: A148-A149.
    3. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study.Lancet 2001; 357: 1576-1582. Go to original source... Go to PubMed...
    4. Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297. Go to original source... Go to PubMed...
    5. European Study Group in Interferon beta-1b in Secondary Progressive MS.Placebo controlled multicentre randomized trial of interferon beta-1b in the treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497. Go to original source...
    6. Fergusson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399. Go to original source... Go to PubMed...
    7. Goodin D.S. Period and pitfalls in the interpretation of clinical trials: A reflection on the recent experience in multiple sclerosis. Neuroepidemiology 1999; 18: 53-63. Go to original source... Go to PubMed...
    8. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis Neurology 58; 2: 169-178.
    9. Goodkin DE, North American SPMS Study Group. The North American Study of interferon beta-1b in secondary progressive multiple sclerosis. 52nd Annual Meeting of the American Academy of Neurology; San Diego: CA, 2000.
    10. Jacobs LD, Beck RW, Simon JH, et al. CHAMPS Study Group. Intramuscular interferon beta -1a therapy initiated during a first demyelinating event in multiple sclerosis.N Eng J Med 2000; 343: 898-904. Go to original source... Go to PubMed...
    11. Jacobs LD, Cookfair DL, Rudick RA, et.al. Intramuscular interferon-beta1a for disease progression in exacerbating - remitting multiple sclerosis.Ann Neurol 1996; 39: 285-294. Go to original source... Go to PubMed...
    12. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing - remitting multiple sclerosis: results of a phase III multicenter, double - blind, placebo controlled trial. Neurology 1995; 45: 1268-1276. Go to original source... Go to PubMed...
    13. PRISMS Study Group. Randomized, double-blind placebo controlled study of interferon beta-1a in relapsing- remmiting multiple sclerosis. Lancet 1998; 352: 1498-1504. Go to original source...
    14. SPECTRIMS Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-1504. Go to original source... Go to PubMed...
    15. The IFNB Multiple Sclerosis Study Group.Interferon-beta1b is effective in remiting and relapsing multiple sclerosis: I.Clinical results of a multicenter, randomized, double blind, placebo controlled trial. Neurology 1993; 43: 662-667. Go to original source... Go to PubMed...
    16. Weinshenker BG. The epidemiology of multiple sclerosis: Neurol Clin 1996; 14: 291-308.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.